It's a brave new world for SomaLogic, as the proteomics biotech rides Eli Casdin's newest SPAC to Nasdaq with $1.2B valuation
Editor’s note: Interested in following biopharma’s fast-paced IPO market? You can bookmark our IPO Tracker here.
The burgeoning field of proteomics has courted heavy investment over the last few years, and on Monday a prominent proteomics biotech scored a new heaping of capital.
SomaLogic announced plans to reverse-merge with Eli Casdin and Keith Meister’s second SPAC on Monday, dubbed CM Life Sciences II, fetching the company a $1.23 billion valuation. The deal gives SomaLogic a cash infusion of $276 million from the SPAC’s IPO last month, as well as a private investment of $375 million from a syndicate of new and returning investors.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.